Aspen manufacturing is expected to drive the group’s earnings growth in the 2027 financial year, as the company works to replace business lost when a major mRNA production contract ended. Aspen Pharmacare forecasts that manufacturing EBITDA will more than double this year, according to its 2026 integrated report. Sterile Operations Offset Contract Loss In the year to end-June, factory EBITDA…
Tag: mRNA
-
Aspen Bets Recovery on Filling Sterile Manufacturing Lines
Aspen Pharmacare’s turnaround now hinges on its sterile manufacturing, the costly network of injectable-drug plants it must fill. This follows last year’s collapse of a major mRNA contract. CEO Stephen Saad sums up the setback with a farmer’s phrase: “We lost the milk but not the cow.” The contract’s loss blew roughly R2bn out of the manufacturing division’s expected earnings.…
-
FDA Unpredictable: Moderna Challenges the Agency
Moderna has launched a rare public attack on the US Food and Drug Administration, warning that an “unpredictable” regulator could weaken America’s lead in drug innovation. During the call, company leaders specifically argued that the FDA’s unpredictable decision-making undermines industry momentum. The comments came during the company’s Friday analyst call. This was just days after the FDA declined to accept…
-
Biovac R&D Lab to Drive Vaccine Manufacturing in Africa
State-backed vaccine manufacturer Biovac has officially launched a new product development laboratory at its Cape Town facility. This move strengthens its capacity to produce vaccines entirely on African soil, from start to finish. The new Biovac R&D lab in Pinelands, Cape Town, will enable scientists to conduct cutting-edge research and development (R&D) on the active pharmaceutical ingredients (APIs) for novel…
-
Aspen Pharmacare Dispute Ends with R500m Settlement
Aspen Pharmacare is set to receive a R500m windfall following the resolution of a damaging legal battle with an undisclosed manufacturing client. This closes a seven-month chapter of significant financial uncertainty for Africa’s largest pharmaceutical producer. In a statement, Aspen advised shareholders that the dispute had been settled. The counterparty is required to pay the R500m “before December 1 2025,…